Skip to main content
Erschienen in: Supportive Care in Cancer 11/2012

01.11.2012 | Original Article

Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer

verfasst von: Aline Lima da Silva Deboni, Adelmo José Giordani, Nilza Nelly Fontana Lopes, Rodrigo Souza Dias, Roberto Araujo Segreto, Siri Beier Jensen, Helena Regina Comodo Segreto

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study is to assess the late oral complications and the role of salivary gland hypofunction in the severity of mucosal reaction in nonsurgical head and neck cancer patients, submitted to radiotherapy with or without chemotherapy.

Methods and materials

Five hundred fifteen charts from patients treated between 2005 and 2009 were reviewed, and 41 patients met the inclusion criteria. Salivary gland function was assessed using a simplified grading system (GSX) and sialometry. Late effects were assessed using the Common Toxicity Criteria (CTC Version 2.0).

Results

The average follow-up was 17.1 (4–51) months. A statistical correlation was found for whole salivary flow rates and the average CTC grades for the mucous membrane. Both unstimulated/stimulated whole salivary flow rates (<0.09 mL/min) were identified as potential risk factors (p < 0.05) and an independent predictor for late mucous membrane toxicity (≥grade 2). A significant correlation was also found between unstimulated salivary flow rates—GSX scores (p = 0.001) and CTC grades for salivary glands. Eighty-five percent of the patients were classified as suffering from salivary gland hypofunction, as well as 58.2 % considered dryness of the mouth the most debilitating complication.

Conclusions

Considering the late effects assessed, the salivary gland hypofunction was the most significant and received the highest morbidity graduation (grade 2/grade 3); xerostomia was also considered the most debilitating complication after treatment. Data show the role of salivary gland hypofunction in the severity of late mucous membrane complication.
Literatur
1.
Zurück zum Zitat Shah JP, Gil Z (2009) Current concepts in management of oral cancer—surgery. Oral Oncol 45:394–401PubMedCrossRef Shah JP, Gil Z (2009) Current concepts in management of oral cancer—surgery. Oral Oncol 45:394–401PubMedCrossRef
2.
Zurück zum Zitat Gallegos-Hernández JF (2006) Head and neck cancer. Risk factors and prevention. Cir Cir 74(4):287–93PubMed Gallegos-Hernández JF (2006) Head and neck cancer. Risk factors and prevention. Cir Cir 74(4):287–93PubMed
4.
Zurück zum Zitat Döbrõssy L (2005) Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 24:9–17PubMedCrossRef Döbrõssy L (2005) Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 24:9–17PubMedCrossRef
5.
Zurück zum Zitat Chua DTT, Tian Y, Wei WI (2007) Late oral complications following radiotherapy for head and neck cancers. Expert Rev Anticancer Ther 7(9):1215–1224PubMedCrossRef Chua DTT, Tian Y, Wei WI (2007) Late oral complications following radiotherapy for head and neck cancers. Expert Rev Anticancer Ther 7(9):1215–1224PubMedCrossRef
6.
Zurück zum Zitat Zackrisson B, Mercke C, Strander H et al (2003) A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 42(5):443–461PubMedCrossRef Zackrisson B, Mercke C, Strander H et al (2003) A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 42(5):443–461PubMedCrossRef
7.
Zurück zum Zitat Al-Sarraf M, Pajak TF, Byhardt RW et al (1997) Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 37(4):777–782PubMedCrossRef Al-Sarraf M, Pajak TF, Byhardt RW et al (1997) Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 37(4):777–782PubMedCrossRef
8.
Zurück zum Zitat Newlin HE, Amdur RJ, Riggs CE et al (2010) Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 116:4533–4540PubMedCrossRef Newlin HE, Amdur RJ, Riggs CE et al (2010) Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 116:4533–4540PubMedCrossRef
9.
Zurück zum Zitat Bentzen SM, Rosenthal DI, Weymuller EA, Trotti A (2007) Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventions. Int J Radiat Oncol Biol Phys 69(2 Suppl):S79–S82PubMedCrossRef Bentzen SM, Rosenthal DI, Weymuller EA, Trotti A (2007) Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventions. Int J Radiat Oncol Biol Phys 69(2 Suppl):S79–S82PubMedCrossRef
10.
Zurück zum Zitat Pignon JP, Maître AL, Bourhis J et al (2007) Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 69(2 Suppl):S112–S114PubMedCrossRef Pignon JP, Maître AL, Bourhis J et al (2007) Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 69(2 Suppl):S112–S114PubMedCrossRef
11.
Zurück zum Zitat Langendijk JA (2007) New developments in radiotherapy of head and neck cancer: higher precision with less patient discomfort? Radiother Oncol 85:1–6PubMedCrossRef Langendijk JA (2007) New developments in radiotherapy of head and neck cancer: higher precision with less patient discomfort? Radiother Oncol 85:1–6PubMedCrossRef
12.
Zurück zum Zitat Trotti A (2000) Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 47(1):1–12PubMedCrossRef Trotti A (2000) Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 47(1):1–12PubMedCrossRef
13.
Zurück zum Zitat Kawashima M (2004) Chemoradiotherapy for head and neck cancer: current status and perspectives. Int J Clin Oncol 9:421–434PubMedCrossRef Kawashima M (2004) Chemoradiotherapy for head and neck cancer: current status and perspectives. Int J Clin Oncol 9:421–434PubMedCrossRef
14.
Zurück zum Zitat Dirix P, Abbeel S, Vanstraelen B et al (2009) Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose–effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 75(2):385–392PubMedCrossRef Dirix P, Abbeel S, Vanstraelen B et al (2009) Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose–effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 75(2):385–392PubMedCrossRef
15.
Zurück zum Zitat Perlmutter MA, Johnson JT, Snyderman CH et al (2002) Functional outcomes after treatment of squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 128:887–891PubMed Perlmutter MA, Johnson JT, Snyderman CH et al (2002) Functional outcomes after treatment of squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 128:887–891PubMed
16.
Zurück zum Zitat Eisbruch A, Rhodus RD et al (2003) The prevention and treatment of radiotherapy-induced xerostomia. Semin Radiat Oncol 13(3):302–308PubMedCrossRef Eisbruch A, Rhodus RD et al (2003) The prevention and treatment of radiotherapy-induced xerostomia. Semin Radiat Oncol 13(3):302–308PubMedCrossRef
17.
Zurück zum Zitat Jensen SB, Pedersen AM, Reibel J, Nauntofte B (2003) Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11:207–225PubMed Jensen SB, Pedersen AM, Reibel J, Nauntofte B (2003) Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11:207–225PubMed
18.
Zurück zum Zitat Saad ED, Hoff PM, Carnelós RP et al (2002) Critérios Comuns de Toxicidade do Instituto Nacional de Câncer dos Estados Unidos (Common toxicity criteria of the National Cancer Institute). Rev Bras Cancerol 48(1):63–96 Saad ED, Hoff PM, Carnelós RP et al (2002) Critérios Comuns de Toxicidade do Instituto Nacional de Câncer dos Estados Unidos (Common toxicity criteria of the National Cancer Institute). Rev Bras Cancerol 48(1):63–96
20.
Zurück zum Zitat Eisbrush A, Rhodus N, Rosenthal D et al (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13(3):226–234CrossRef Eisbrush A, Rhodus N, Rosenthal D et al (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13(3):226–234CrossRef
21.
Zurück zum Zitat Radiation Therapy Oncology Group (1999) A phase III study to test the efficacy of the prophylatic use of oral pilocarpine to reduce hyposalivation and mucositis associated with curative radiation therapy in head and neck cancer patients. RTOG97-09. Philadelphia, PA: Radiation Therapy Oncology Group. www.rtog.org/members/protocols/97-09/97-09.pdf. Accessed 20 Jan 2010 Radiation Therapy Oncology Group (1999) A phase III study to test the efficacy of the prophylatic use of oral pilocarpine to reduce hyposalivation and mucositis associated with curative radiation therapy in head and neck cancer patients. RTOG97-09. Philadelphia, PA: Radiation Therapy Oncology Group. www.​rtog.​org/​members/​protocols/​97-09/​97-09.​pdf. Accessed 20 Jan 2010
22.
Zurück zum Zitat Navazesh M, Christensen CM (1982) A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 61(10):1158–62PubMedCrossRef Navazesh M, Christensen CM (1982) A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 61(10):1158–62PubMedCrossRef
23.
Zurück zum Zitat Adelstein DJ (2007) Concurrent chemoradiotherapy in the management of squamous cell cancer of the oropharynx: current standards and future directions. Int J Radiat Oncol Biol Phys 69(2 Suppl):S37–S39PubMedCrossRef Adelstein DJ (2007) Concurrent chemoradiotherapy in the management of squamous cell cancer of the oropharynx: current standards and future directions. Int J Radiat Oncol Biol Phys 69(2 Suppl):S37–S39PubMedCrossRef
24.
Zurück zum Zitat Furness S, Glenny AM, Worthington HV et al (2010) Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews, 9: CD006386 Furness S, Glenny AM, Worthington HV et al (2010) Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews, 9: CD006386
25.
Zurück zum Zitat Stone HB, Coleman CN, Anscher MS, McBride WH (2003) Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 4:529–536PubMedCrossRef Stone HB, Coleman CN, Anscher MS, McBride WH (2003) Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 4:529–536PubMedCrossRef
26.
Zurück zum Zitat Givens DJ, Karnell LH, Gupta AK et al (2009) Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 135(12):1209–1217PubMedCrossRef Givens DJ, Karnell LH, Gupta AK et al (2009) Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 135(12):1209–1217PubMedCrossRef
27.
Zurück zum Zitat Withers HR, Peters LJ, Taylor JMG (1995) Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: patterns of fractionation study of radiobiology. Int J Radiat Oncol Biol Phys 33(3):563–568PubMedCrossRef Withers HR, Peters LJ, Taylor JMG (1995) Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: patterns of fractionation study of radiobiology. Int J Radiat Oncol Biol Phys 33(3):563–568PubMedCrossRef
28.
Zurück zum Zitat Citrin D, Mansueti J, Likhacheva A (2009) Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 74(4):1040–1046PubMedCrossRef Citrin D, Mansueti J, Likhacheva A (2009) Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 74(4):1040–1046PubMedCrossRef
29.
Zurück zum Zitat Chen AM, Li BQ, Jennelle RLS et al (2010) Late esophageal toxicity after radiation therapy for head and neck cancer. Head Neck 32:178–183PubMedCrossRef Chen AM, Li BQ, Jennelle RLS et al (2010) Late esophageal toxicity after radiation therapy for head and neck cancer. Head Neck 32:178–183PubMedCrossRef
30.
Zurück zum Zitat Power DA (2005) Late effects of radiotherapy: how to assess and improve outcomes. Br J Radiol 78:150–152PubMedCrossRef Power DA (2005) Late effects of radiotherapy: how to assess and improve outcomes. Br J Radiol 78:150–152PubMedCrossRef
31.
Zurück zum Zitat Cooper JS, Fu K, Marks J, Silverman S (1995) Late effects of radiation therapy in the head and neck region. Int J Radiation Oncology Biol Phys 31(5):1141–1164CrossRef Cooper JS, Fu K, Marks J, Silverman S (1995) Late effects of radiation therapy in the head and neck region. Int J Radiation Oncology Biol Phys 31(5):1141–1164CrossRef
32.
Zurück zum Zitat Vissink A, Jansma J, Spijkervet FKL (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14(3):199–212PubMedCrossRef Vissink A, Jansma J, Spijkervet FKL (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14(3):199–212PubMedCrossRef
33.
Zurück zum Zitat Olmi P, Crispino S, Fallai C et al (2006) Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55(1):78–92CrossRef Olmi P, Crispino S, Fallai C et al (2006) Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55(1):78–92CrossRef
34.
Zurück zum Zitat Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582–3589PubMedCrossRef Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582–3589PubMedCrossRef
35.
Zurück zum Zitat Fischer DJ, Epstein JB (2008) Management of patients who have undergone head and neck cancer therapy. Dent Clin N Am 52:39–60PubMedCrossRef Fischer DJ, Epstein JB (2008) Management of patients who have undergone head and neck cancer therapy. Dent Clin N Am 52:39–60PubMedCrossRef
36.
Zurück zum Zitat Epstein JB, Stevensen-Moore P (2001) Periodontal disease and periodontal management in patients with cancer. Oral Oncol 37:613–619PubMedCrossRef Epstein JB, Stevensen-Moore P (2001) Periodontal disease and periodontal management in patients with cancer. Oral Oncol 37:613–619PubMedCrossRef
37.
Zurück zum Zitat Eisbruch A, Kim HM, Terrel JE et al (2001) Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50(3):695–704PubMedCrossRef Eisbruch A, Kim HM, Terrel JE et al (2001) Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50(3):695–704PubMedCrossRef
38.
Zurück zum Zitat Sonis ST, Fey EG (2002) Oral complications of cancer therapy. Oncology 16(5):680–686PubMed Sonis ST, Fey EG (2002) Oral complications of cancer therapy. Oncology 16(5):680–686PubMed
39.
Zurück zum Zitat Yeh SA, Tang Y, Lui CC et al (2005) Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 62(3):672–679PubMedCrossRef Yeh SA, Tang Y, Lui CC et al (2005) Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 62(3):672–679PubMedCrossRef
40.
Zurück zum Zitat Fu KK, Pajak TF, Marcial VA et al (1995) Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys 32(3):577–588PubMedCrossRef Fu KK, Pajak TF, Marcial VA et al (1995) Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys 32(3):577–588PubMedCrossRef
41.
Zurück zum Zitat Sreebny LM, Valdini A (2006) Xerostomia. Part I: relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66(4):451–458CrossRef Sreebny LM, Valdini A (2006) Xerostomia. Part I: relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66(4):451–458CrossRef
42.
Zurück zum Zitat Guchelaar HJ, Vermes A, Meerwaldt JH (1997) Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 5:281–288PubMedCrossRef Guchelaar HJ, Vermes A, Meerwaldt JH (1997) Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 5:281–288PubMedCrossRef
43.
Zurück zum Zitat Kaplan I, Zuk-Paz L, Wolff A (2008) Association between salivary flow rates, oral symptoms, and oral mucosal status. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:235–41PubMedCrossRef Kaplan I, Zuk-Paz L, Wolff A (2008) Association between salivary flow rates, oral symptoms, and oral mucosal status. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:235–41PubMedCrossRef
44.
Zurück zum Zitat Jensen SB et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 18(8):1061–79PubMedCrossRef Jensen SB et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 18(8):1061–79PubMedCrossRef
45.
Zurück zum Zitat Rose-Ped AM, Bellm LA, Epstein JB et al (2002) Complications of radiation therapy for head and neck cancers. Cancer Nurs 25(6):461–465PubMedCrossRef Rose-Ped AM, Bellm LA, Epstein JB et al (2002) Complications of radiation therapy for head and neck cancers. Cancer Nurs 25(6):461–465PubMedCrossRef
Metadaten
Titel
Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer
verfasst von
Aline Lima da Silva Deboni
Adelmo José Giordani
Nilza Nelly Fontana Lopes
Rodrigo Souza Dias
Roberto Araujo Segreto
Siri Beier Jensen
Helena Regina Comodo Segreto
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1418-7

Weitere Artikel der Ausgabe 11/2012

Supportive Care in Cancer 11/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.